{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-032043","form_type":"8-K","ticker":"IVF","cik":"0001417926","company_name":"INVO Fertility, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.576462+00:00","generated_at":"2026-06-21T19:49:02.210195+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"INVO Bioscience Q3 revenue ex-license $235K, up 484% YoY; cash $0.3M, closes $0.35M debt","bullets":["Revenue (ex-license) $235,321 (+484% YoY, +61% sequential); clinic revenue $176,395 (+370%), product sales $58,926 (+2,012%).","Combined clinic revenue (consolidated + equity) $450,131 (+1,100% YoY, +111% sequential).","Cash $0.3M at Sept 30; raised $0.35M in interim demand notes post-quarter; seeking additional funding.","Adjusted EBITDA -$2.0M vs -$1.6M; gross margin 54% vs 49% adjusted prior year; no GAAP net income disclosed.","Completed due diligence on clinic acquisition; Tampa INVO Center expected Q1 2023; updated 510(k) filed for 5-day incubation."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-032043","json":"https://secwatch.observer/filing/0001493152-22-032043.json","markdown":"https://secwatch.observer/filing/0001493152-22-032043.md","text":"https://secwatch.observer/filing/0001493152-22-032043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417926/000149315222032043/0001493152-22-032043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417926/000149315222032043/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:49:02.210195+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c9958695635232f42650512da6fa7d23521f9b55","claim":"INVO Fertility, Inc. reported the third quarter ended September 30, 2022 results: revenue $235,321.","evidence_excerpt":"Revenue for the three months ended September 30, 2022, was $235,321 compared to $218,874 for the three months ended September 30, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315222032043/0001493152-22-032043-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$235,321"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}